I-Mab Reports Positive Interim Analysis from Phase 2/3 Study of its GM-CSF Antibody Plonmarlimab to Treat Patients with Severe COVID-19; Co. Reports 'treatment was well tolerated with no significant safety concerns in patients with severe COVID-19'